Stongbridge Biopharma to be acquired by Xeris Pharmaceuticals

Irish company valued at $267 million ahead of buyout by American pharma firm

25th May, 2021
Stongbridge Biopharma to be acquired by Xeris Pharmaceuticals
The new, merged entity will be called Xeris Biopharma Holdings and is expected to trade on the Nasdaq

Xeris Pharmaceuticals, the US pharma company with a market cap of $217 million, announced it is to acquire Stongbridge Biopharma, the Irish public limited company.

As part of the deal, Strongbridge has been valued at $267 million.

The merger aims to create a leading company in endocrinology and rare diseases with a pipeline of drug development. Strongbridge develops and commercialises therapies for people with rare diseases and significant unmet needs.

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Related Stories

Turnover down 38% at Airbnb’s Irish unit as Covid hits revenue